By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Reata Pharmaceuticals, Inc. 

1950 Stemmons Freeway, Suite 5001

Dallas  Texas  75207  U.S.A.
Phone: 214-800-8700 Fax: 214-722-0867


SEARCH JOBS


Industry
Pharmaceutical






Company News
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation For Omaveloxolone For The Treatment Of Friedreich’s Ataxia 6/22/2017 11:16:39 AM
Reata Pharmaceuticals, Inc. Announces Positive Data From Part One Of Moxie Trial Of Omaveloxolone For Friedreich’s Ataxia 6/2/2017 8:30:14 AM
Reata Pharmaceuticals, Inc. Announces First Quarter 2017 Financial And Operating Results 5/11/2017 11:15:57 AM
Reata Pharmaceuticals, Inc. Secures $35 Million Term Loan Facility 4/3/2017 1:57:42 PM
Reata Pharmaceuticals, Inc. Appoints David Chapman< As Vice President, Marketing 3/24/2017 8:16:29 AM
Reata Pharmaceuticals, Inc. Announces Fourth Quarter And Full Year 2016 Financial And Operating Results 3/3/2017 9:15:38 AM
Reata Pharmaceuticals, Inc. Announces The Retirement Of Board Member Dennis Stone, M.D., And The Addition Of New Board Member William D. Mcclellan, Jr. 3/2/2017 8:58:52 AM
Reata Pharmaceuticals, Inc. Announces Initiation Of Phase II/III Study Of Bardoxolone Methyl In The Treatment Of Chronic Kidney Disease Due To Alport Syndrome 2/23/2017 8:38:46 AM
Reata Pharmaceuticals, Inc. Announces Requested Withdrawal Of Registration Statement Due To Adverse Market Conditions 12/12/2016 7:56:21 AM
Reata Pharmaceuticals, Inc. Announces Filing Of Registration Statement For Proposed Public Offering 12/6/2016 7:53:11 AM
123456
//-->